1. Persida Tahiri, PharmD Candidate 2016 Cone Health Family Medicine
News You Can Use…
Persida Tahiri, PharmD Candidate 2016
Pete Koval, PharmD
Cone Health Family Medicine
February 2016

2. P & T Committee Veltassa (patiromer) added to the formulary
New oral potassium binder FDA approved for treatment of chronic hyperkalemia in adults
Not for acute treatment
Use at Cone Health: only as continuation of prior to admission therapy
01/20/16 Cone Health P & T

3. P & T Committee
Praxbind (idarucizumab) gained FDA approval as first available reversal agent for oral anticoagulant Pradaxa (dabigatran)
Use at Cone Health: Only for patients who have taken dabigatran and have uncontrollable or life-threatening bleeding or require immediate invasive procedure
01/20/16 Cone Health P & T

4. New Indication
Consentyx (secukinumab) gained FDA approval for ankylosing spondylitis (psoriatic arthritis)
Already approved for treatment of moderate to severe plaque psoriasis in adult patients
Medscape.com, N Engl J Med. 2015;373:

5. New Guidelines New AHA/ASA statement on expanding use of tPA in stroke
New Alteplase patient information has entirely removed some exclusions and contraindications including:
Prior stroke
Seizure at onset of stroke
History of ICH (left warning for recent ICH)
Low blood glucose (previously < 50 mg/dL)
Mild stroke
Neuroimaging findings
1/15/2016 Stroke Feb 2016

6. Pen Device Approval FDA approves first U-500 insulin pen device
Humulin R U-500 KwikPen by Eli Lilly
It is the same size as the other Lilly KwikPens and dials in five-unit increments
01/27/2015 medscape.com

7. New Research
Kalydeco (ivacaftor) a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator beneficial in children 2-5 yo
Discontinue in patient with ALT or AST levels ≥ 5xULN. Consider risk benefit after resolution of transaminase elevations
1/21/2016 medicalpress.com

8. Drug Approval
FDA approves Zepatier (elbasvir and grazoprevir) with or without ribavirin for treatment of chronic hepatitic C genotypes 1 and 4 infections in adult patients
Another treatment option that doesn’t require use of interferon
1/28/2016 fda.gov

9. Speedy FDA Review
Hepatitis C combo sofosbuvir/velpatasvir was granted speedy review
It is beneficial in Hepatitis C genotypes 1,2,4,5 and 6
Efficacy of % has been demonstrated with this combination
1/5/2016 fiercepharma.com, NEJM 2015; 373:

10. New Formulation
FDA approves Dexilant SoluTab (dexlansoprazole) delayed release orally disintegrating tablets (ODT)
Indicated for treatment of GERD and maintenance of healed erosive esophagitis and relief of heartburn in adults ≥ 18 yo
1/29/

11. Drug Approval
FDA approves Adzenys XR-ODT (amphetamine) for treatment of ADHD in patients ≥ 6yo
This oral disintegrating tablet is dosed once daily, available in 6 dosage strengths, equivalent to the Adderall XR dosage strengths
1/27/2016 reuters.com

12. Patent Expirations
Crestor (rosuvastatin) patent expected to expire in July 2016
01/18/2016 forbes.com